IFN-γ and IL-12 strongly influence dasatinib efficacy in ALL. (A) Leukemia burden is plotted as a function of time with dasatinib treatment for B6 or Ifng-KO mice. The shaded area indicates the duration of dasatinib treatment. (B) Kaplan-Meier survival curve of leukemia-bearing mice with dasatinib treatment or with vehicle control. (C) Most of the Ifng-KO mice relapsed with leukemia harboring a drug-resistant BCR-ABL1 T315I mutation. (D) The relapsed ALL cells from Ifng-KO mice showed acquired resistance to dasatinib in vitro. (E) Leukemia burden is plotted as a function of time for mice treated with dasatinib plus PBS or dasatinib plus IL-12. The shaded area indicates the duration of therapy. (F) Kaplan-Meier survival curve of leukemia-bearing mice treated with dasatinib/vehicle or dasatinib/vehicle plus IL-12. The difference in overall survival was detected by log-rank (Mantel-Cox) test. ns, not significant; PBS, phosphate-buffered saline; WT, wild type.